We only have this paper's title and publication details.
Read it at the sourceEffects of targeting MUC1-C on effectors of the type I and II IFN pathways.
No takes yet. Share an insight, caveat, or question.
Nakashoji et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: